~~<i id='5D2893D77A'><strike id='5D2893D77A'><tt id='5D2893D77A'><pre id='5D2893D77A'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：explore 2025-09-06 10:46:50 Page View：37878

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What is microchimerism and how does it affect maternal health?
Next article： Psychedelics group wrestles with new pharma identity

explore

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

After Sarepta trial failure, Duchenne families brace for more debate

KristofferTripplaar/SipaviaAPTohearSareptaCEODougIngramtellit,theresultsMondayafternoonfromalargetri

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

RussianPresidentVladimirPutinattendsameetingoftheShanghaiCooperationOrganisation(SCO)HeadsofStateCou

WSS

leisure time

leisure time

comprehensive

explore

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on